Phosphate Reports – IMPHOS http://imphos.org/ Fri, 24 Sep 2021 11:01:00 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://imphos.org/wp-content/uploads/2021/08/IMPHOS-icon-150x150.jpg Phosphate Reports – IMPHOS http://imphos.org/ 32 32 Nabriva Therapeutics to present its data at IDWeek 2021 https://imphos.org/nabriva-therapeutics-to-present-its-data-at-idweek-2021/ https://imphos.org/nabriva-therapeutics-to-present-its-data-at-idweek-2021/#respond Fri, 24 Sep 2021 11:01:00 +0000 https://imphos.org/nabriva-therapeutics-to-present-its-data-at-idweek-2021/ DUBLIN, Ireland and FORT WASHINGTON, Pa., September 24, 2021 (GLOBE NEWSWIRE) – Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the presentation of the data at the Infectious Disease Society of America (IDSA) IDWeek ™ 2021 which will run […]]]>

DUBLIN, Ireland and FORT WASHINGTON, Pa., September 24, 2021 (GLOBE NEWSWIRE) – Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the presentation of the data at the Infectious Disease Society of America (IDSA) IDWeek ™ 2021 which will run virtually from September 29 to October 3, 2021.

Nabriva, with his collaborators, will present a poster presentation on the in vitro activity of lefamulin against Staphylococcus aureus isolated from the lower respiratory tract of children with cystic fibrosis. XENLETA® (lefamulin) is a first-class pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CAP).

PRESENTATION:

Session title: Respiratory infections – Bacterial
Title of the poster: “In vitro activity of Lefamulin against Staphylococcus aureus isolated from the lower respiratory tract of children with cystic fibrosis’
Session ID: 1058520
Speaker: Dr Helio S. Sader, MD, Ph.D., FIDSA (Senior Director, JMI Laboratories)

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics Receives U.S. Food and Drug Administration Approval For XENLETA® (injection of lfamulin, lfamulin tablets), the first systemic antibiotic based on pleuromutilin for community bacterial pneumonia (CAP). Nabriva Therapeutics is also developing CONTEPO ™ (fosfomycin) for injection, a first-class epoxy antibiotic with potential for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, NJ, USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and some of its territories.

Forward-looking statements

All statements in this press release regarding Nabriva Therapeutics ‘future expectations, plans and prospects, including, but not limited to, statements about Nabriva Therapeutics’ ability to promote XENLETA and SIVEXTRO, to stimulate growth in demand for prescriptions and drive sales growth, the potential patient benefits of SIVEXTRO and XENLETA, the market opportunity for SIVEXTRO and XENLETA, the availability of SIVEXTRO through leading specialist wholesalers in United States, the impact on Nabriva Therapeutics’ reported revenues from anticipated sales of SIVEXTRO, its liquidity sufficiency and other statements containing the words “anticipate”, “believe”, “estimate”, “expect” to ”,“ intend ”,“ may ”,“,. “” Will “,” would “,” could “,” should “,” continue “and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those shown by these forward-looking statements due to various important factors, including: the ability of Nabriva Therapeutics to comply with its obligations under its loan agreement with Hercules, the ability of Nabriva Therapeutics to maintain the terms of the distribution agreement for exclusively distribute and promote SIVEXTRO, including its ability to maintain sufficient commercial infrastructure to promote and distribute SIVEXTRO, the extent of business disruptions resulting from the infection causing the COVID-19 outbreak or crises similar public health, the ability to retain and hire key personnel, the availability of adequate additional funding at c conditions are acceptable or not at all and other important factors as set out in Nabriva Therapeutics’ annual and quarterly reports and other documents filed with the SEC. In addition, the forward-looking statements included in this press release represent the views of Nabriva Therapeutics as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments could change its point of view. However, although Nabriva Therapeutics may choose to update these forward-looking statements at some time in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be taken as representing the views of Nabriva Therapeutics as of a date subsequent to the date of this press release.

CONTACTS:

For investors

Kim anderson
Nabriva Therapeutics plc
ir@nabriva.com

For the media

Andrea Greif
Ogilvy
andrea.greif@ogilvy.com
914-772-3027


Source link

]]>
https://imphos.org/nabriva-therapeutics-to-present-its-data-at-idweek-2021/feed/ 0
Ascendis Pharma A / S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Further Normalization and Stabilization of BMD Z Scores Between 26 and 58 Weeks https://imphos.org/ascendis-pharma-a-s-announces-mean-bone-mineral-density-bmd-data-from-phase-2-path-forward-trial-demonstrating-further-normalization-and-stabilization-of-bmd-z-scores-between-26-and-58-weeks/ https://imphos.org/ascendis-pharma-a-s-announces-mean-bone-mineral-density-bmd-data-from-phase-2-path-forward-trial-demonstrating-further-normalization-and-stabilization-of-bmd-z-scores-between-26-and-58-weeks/#respond Wed, 22 Sep 2021 20:29:27 +0000 https://imphos.org/ascendis-pharma-a-s-announces-mean-bone-mineral-density-bmd-data-from-phase-2-path-forward-trial-demonstrating-further-normalization-and-stabilization-of-bmd-z-scores-between-26-and-58-weeks/ Receive instant alerts for news on your actions. Claim your 1-week free trial for StreetInsider Premium here. – Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with previously reported observed bone remodeling markers – COPENHAGEN, Denmark, September 22, 2021 (GLOBE NEWSWIRE) – Ascendis Pharma A / […]]]>

Receive instant alerts for news on your actions. Claim your 1-week free trial for StreetInsider Premium here.


– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with previously reported observed bone remodeling markers –

COPENHAGEN, Denmark, September 22, 2021 (GLOBE NEWSWIRE) – Ascendis Pharma A / S (Nasdaq: ASND), a biopharmaceutical company using its innovative TransCon ™ technologies to potentially create new treatments to make a significant difference in the lives of patients, today announced 58-week BMD data from a central lab reading of the PaTH Forward trial, a global Phase 2 trial of its investigational product candidate TransCon PTH in adult subjects with hypoparathyroidism (HP) .

“HP patients, compared to people with normal parathyroid function, have insufficient parathyroid hormone (PTH) levels and low rates of PTH-induced skeletal remodeling, resulting in above average bone mineral density and potentially increased risk of fractures and other negative health effects. Said Aimee Shu, MD, Ascendis Pharma vice president of clinical development, Endocrine Medical Sciences. “We designed TransCon PTH as a single daily injection to restore physiological levels of PTH, 24 hours a day. In PaTH Forward, the mean BMD Z scores, which parallel serum markers of bone turnover, tended towards stabilization and normalization continues at 58 weeks. We believe this is an indicator that TransCon PTH has the potential to normalize calcium metabolism in the body over time.

About the Week 58 AnalysisBMD was measured with non-invasive DXA, a low-exposure radiation technology widely used to identify people at risk for bone fractures. The results were read and reported by a central laboratory.

Z scores of mean bone mineral density by DXA *
Anatomical region m Reference Week 26 Week 58
Lumbar spine (L1-L4) 42 1.6 1.0 0.9
Femoral neck 43 1.0 0.5 0.5
Total hip 43 1.0 0.6 0.5
Forearm / 1/3 radius 41 0.3 0.3 0.3

* From the reading of the central laboratory

About TransCon™ PTH1TransCon PTH is a long-acting, once-daily, investigational prodrug of parathyroid hormone (PTH[1-34]) in development as a treatment for hypoparathyroidism (HP) in adults designed to restore PTH to physiological levels for 24 hours a day to treat both short-term symptoms and complications long-term illness. TransCon PTH has been granted orphan drug status in the United States, European Union and Japan.

About hypoparathyroidism (HP) 2,3,4,5,6,7HP is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH) which plays an essential role in controlling systemic levels of calcium, phosphate and calcitriol (vitamin D active) and is essential for many key biological functions. HP affects approximately 400,000 patients in the United States, Europe, Japan, South Korea and Greater China, the majority of whom develop the disease as a result of injury or accidental removal of the parathyroid glands during thyroid surgery. Patients often experience a decrease in their quality of life. Short-term symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paraesthesia), memory loss, poor judgment, and headache. In the long term, this complex disorder can increase the risk of major complications, such as extraskeletal calcium deposits occurring in the brain, lens, and kidneys, which can lead to kidney failure.

HP remains among the few states of hormonal insufficiency without approved replacement therapy that restores the missing hormone to physiological levels. Standard of care with active vitamin D analogues and calcium supplementation does not completely control the disease and may contribute to the risk of kidney disease. As a result, patients with HP have an estimated 4 to 8 times greater risk of kidney disease than healthy controls.

About Ascendis Pharma A / SAscendis Pharma applies its innovative platform technology to create a leading fully integrated biopharmaceutical company focused on improving the lives of patients. Guided by its core values ​​of patients, science and passion, the company uses its TransCon technologies to create new therapies potentially best in class.

Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Heidelberg and Berlin, Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey. Please visit www.ascendispharma.com to learn more.

Forward-looking statementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this press release regarding the future operations, plans and objectives of the management of Ascendis are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the design of Ascendis of TransCon PTH as a daily injection to restore physiological levels of PTH, 24 hours a day; (ii) Ascendis’ belief that the observed BMD data indicate that TransCon PTH has the potential to normalize calcium metabolism in the body over time; (iii) Ascendis ‘ability to apply its platform technology to build a leading fully integrated biopharmaceutical company, (iv) Ascendis’ product pipeline and its expansion into additional therapeutic areas and (v) Ascendis’ expectations regarding its ability to use its TransCon technologies to create new, potentially best-in-class therapies. Ascendis may not carry out the plans, realize the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from Ascendis’ forward-looking statements, including: reliance on third party manufacturers to supply TransCon hGH, the SKYTROFA® autoinjector and other United States and clinical studies; unanticipated safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the commercialization of lonapegsomatropin-tcgd in the United States and the further development of TransCon hGH, expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or d ‘other development programs, sales, general and administrative costs, other research and development costs and the activity of Ascedis in general; delays in the development of its oncology, TransCon hGH, TransCon PTH and TransCon CNP programs or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays ; reliance on third party manufacturers to supply study drug for planned clinical studies; Ascendis’ ability to secure additional funding, if necessary, to support its business operations and the effects on its business of the global COVID-19 pandemic. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with Ascendis ‘business in general, see Ascendis’ annual report on Form 20- F filed with the United States Securities and Exchange Commission (SEC) on March 10, 2021 and other future Ascendis reports filed or submitted to the SEC. Forward-looking statements do not reflect the potential impact of any future licenses, collaborations, acquisitions, mergers, disposals, joint ventures or investments that Ascendis may enter into or make. Ascendis assumes no obligation to update forward-looking statements, except as required by law.

SKYTROFA, Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are registered trademarks of the Ascendis Pharma group. © September 2021 Ascendis Pharma A / S.

— Footnotes: 1 Karpf DB, et al. J Bone Miner Res. 2020; x: 1-11.2 Mannstadt M, et al. Nature Reviews 2017, 3: 170553 Ascendis Pharma HP Patient Experience Research. 4 Hadker N, et al. Endo practice. 2014, 20 (7); 671-679. 5 Powers J, et al. J Bone Miner Res 2013, 28: 2570-2576.6 Mitchell DM, et al. J Clin Endocrinol Metab 2012, 97 (12): 4507-45147 Underbjerg L, et al. J Bone Miner Res 2013, 28: 2277-2285

Main logo

Source: Ascendis Pharma


Source link

]]>
https://imphos.org/ascendis-pharma-a-s-announces-mean-bone-mineral-density-bmd-data-from-phase-2-path-forward-trial-demonstrating-further-normalization-and-stabilization-of-bmd-z-scores-between-26-and-58-weeks/feed/ 0
A single mutation weakens symbiont-induced reproductive manipulation by reducing the efficiency of deubiquitylation https://imphos.org/a-single-mutation-weakens-symbiont-induced-reproductive-manipulation-by-reducing-the-efficiency-of-deubiquitylation/ https://imphos.org/a-single-mutation-weakens-symbiont-induced-reproductive-manipulation-by-reducing-the-efficiency-of-deubiquitylation/#respond Tue, 21 Sep 2021 18:31:02 +0000 https://imphos.org/a-single-mutation-weakens-symbiont-induced-reproductive-manipulation-by-reducing-the-efficiency-of-deubiquitylation/ Importance Wolbachia are mother-transmitted bacteria that infect most insects, making them the most common endosymbionts. Wolbachia achieves this status by manipulating the host’s reproduction. For example, many Wolbachia cause cytoplasmic incompatibility (CI) which kills uninfected embryos. In females, Wolbachia can save ICs, promoting their spread at high frequencies in host populations. The strength of the […]]]>

Importance

Wolbachia are mother-transmitted bacteria that infect most insects, making them the most common endosymbionts. Wolbachia achieves this status by manipulating the host’s reproduction. For example, many Wolbachia cause cytoplasmic incompatibility (CI) which kills uninfected embryos. In females, Wolbachia can save ICs, promoting their spread at high frequencies in host populations. The strength of the CI varies by nature from weak to strong. Above all, a strong CI allows Wolbachia biological control strategies in mosquito systems, which protect millions of people against arboviruses. However, theory predicts that natural selection does not work to preserve the genes that cause CI, suggesting that mutations can disrupt it. We show that a single naturally observed mutation weakens CI by reducing desubiquitylation. These findings help to elucidate the molecular basis of reproductive manipulations induced by symbionts.

Abstract

Animals interact with microbes that affect their performance and fitness, including endosymbionts that reside inside their cells. Maternal transmission Wolbachia bacteria are the most common known endosymbionts, largely due to their manipulation of host reproduction. For example, many Wolbachia cause cytoplasmic incompatibility (CI) which reduces the embryonic viability of the host when Wolbachia-modified sperm fertilize uninfected eggs. Operate called caf Control IC, and a single factor (CA FA) saves him, providing Wolbachia-infected females a fitness benefit. Despite the prevalence of CI in nature, theory indicates that natural selection does not act to maintain CI, which varies widely in strength. Here, we investigate the genetic and functional basis for the variation in CI strength observed in sisters Wolbachia who infects Drosophila melanogaster subgroup hosts. We cloned, sequenced Sanger and expressed caf weak CI directories causing wYak in it Yakuba Drosophila, revealing mutations suspected of weakening the CI compared to the model wMel in D. melanogaster. A single valine-leucine mutation in the deubiquitylation domain (DUB) of wYak cafB counterpart (cidB) suppresses a type CI phenotype in yeast. The same mutation reduces both the efficiency of DUB in vitro and the strength of the transgenic IC in the fly, each approximately twice. Our results match hypomorphic transgenic IC with reduced DUB activity and indicate that deubiquitylation is central to induction of IC in cid systems. We also characterize the effects of other genetic variations by distinguishing wLike Mel caf. Above all, the strength of the CI determines Wolbachia in natural systems and directly influences the efficiency of Wolbachia biological control strategies in transfected mosquito systems. These approaches rely on a strong CI to reduce human disease.

Footnotes

  • Author contributions: research designed by JFB, KVV and BSC; JFB, KVV, DEA and BSC have done research; JFB, DEA and BSC provided new reagents / analytical tools; JFB, KVV, DEA and BSC analyzed the data; JFB and BSC provided financing for the acquisition; BSC coordinated the research; and JFB, KVV, DEA and BSC wrote the article.

  • The authors declare no competing interests.

  • This article is a direct PNAS submission.

  • This article contains additional information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2113271118/-/DCSupplemental.

Data availability

All study data is included in the article and / or additional information.

  • Accepted August 16, 2021.


Source link

]]>
https://imphos.org/a-single-mutation-weakens-symbiont-induced-reproductive-manipulation-by-reducing-the-efficiency-of-deubiquitylation/feed/ 0
Orthofix Announces Full Market Launch of Opus Mg Set – A Curable Magnesium Bone Filler for Orthopedic Procedures | Business https://imphos.org/orthofix-announces-full-market-launch-of-opus-mg-set-a-curable-magnesium-bone-filler-for-orthopedic-procedures-business/ https://imphos.org/orthofix-announces-full-market-launch-of-opus-mg-set-a-curable-magnesium-bone-filler-for-orthopedic-procedures-business/#respond Tue, 21 Sep 2021 11:02:58 +0000 https://imphos.org/orthofix-announces-full-market-launch-of-opus-mg-set-a-curable-magnesium-bone-filler-for-orthopedic-procedures-business/ LEWISVILLE, Texas – (BUSINESS WIRE) – Sep 21, 2021– Orthofix Medical Inc. (NASDAQ: OFIX), a global medical device company specializing in spine and orthopedics, today announced the full market launch of Set of mg Opus ™ osteoconductive scaffolding, a synthetic magnesium-based bone filler for orthopedic procedures. This press release features multimedia. See the full version […]]]>

LEWISVILLE, Texas – (BUSINESS WIRE) – Sep 21, 2021–

Orthofix Medical Inc. (NASDAQ: OFIX), a global medical device company specializing in spine and orthopedics, today announced the full market launch of Set of mg Opus ™ osteoconductive scaffolding, a synthetic magnesium-based bone filler for orthopedic procedures.

This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/20210921005189/en/

Image of the Orthofix Opus Mg set in injectable form. (Photo: Business Wire)

Opus Mg Set provides a procedure specific solution for orthopedic fracture care and trauma applications by filling voids or non-structural bone gaps during surgery. Available in both moldable and injectable form, Opus Mg Set provides immediate compressive strength at the surgical site after implantation. When injected or placed into voids or bone spaces, Opus Mg Set forms a supportive scaffold to help facilitate the natural process of bone healing.

“We are delighted to add the Opus Mg Set Osteoconductive Scaffolding to our comprehensive portfolio of biological solutions,” said Jon Serbousek, President and CEO of Orthofix. “Opus Mg Set is another example of our commitment to innovative biological solutions that will meet the needs of our valued surgeon customers and their patients. “

Opus Mg Set is a synthetic solution based on magnesium. Magnesium phosphate crystallizes to give thixotropic properties and high compressive strength. Additionally, magnesium is important in bone healing as it promotes the proliferation of osteogenic cells, improves new bone formation, and stimulates protein for bone regeneration. Preclinical studies with Opus Mg Set have shown greater than 80% bone turnover in 26 weeks.

For those attending the American Orthopedic Foot & Ankle Society Annual Meeting in Charlotte, NC, please visit Orthofix booth # 414 to learn more about the Opus Mg Set Osteoconductive Scaffolding.

About Orthofix

Orthofix Medical Inc. is a global medical device focused on the spine and orthopedics. The company’s mission is to provide innovative, quality-driven solutions in partnership with healthcare professionals to improve the lives of patients. Based in Lewisville, Texas, Orthofix orthopedic and spinal products are distributed in more than 60 countries through the company’s sales representatives and distributors. For more information, please visit www.Orthofix.com.

Forward-looking statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, regarding our business and financial prospects, which are based on about our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “intention” , “Predicted”, “potential” or “continue” or any other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in part I, item 1A under the heading Risk factors in our report. annual on Form 10-K for the fiscal year ended December 31, 2020 (the “Form 10-K 2020”). In addition to the risks described therein, factors that could cause or contribute to such differences may include, but are not limited to: the risk that surgeons may be slow to adopt the Opus Mg Set osteoconductive scaffold; the risk that future patient studies or clinical experience and data may indicate that treatment with the Opus Mg Set osteoconductive scaffold does not improve patient outcomes as much as previously believed, or calls into question the benefits of its use for patients, hospitals and surgeons; the risk that the product will not perform as intended and therefore not achieve commercial success; the risk that competitors will develop higher quality products or occupy a more important position in the market allowing a more successful commercialization; the risk that insurers will refuse to reimburse healthcare providers for the use of our products.

This list of risks, uncertainties and other factors is not complete. We discuss in more detail some of these matters, as well as certain risk factors that could affect our business, financial condition, results of operations and prospects, in reports that we file from time to time with the Commission. SEC, which are available for reading at www.sec.gov. Some or all of the forward-looking statements we make may prove to be incorrect (due to inaccurate assumptions that we make or otherwise), and our results and actual results may differ materially from those expressed in such forward-looking statements. You should not place undue reliance on these forward-looking statements. In addition, any forward-looking statement speaks only as of the date hereof, unless it is specifically indicated that it is made on a different date. We assume no obligation to update, and expressly disclaim any obligation to update, our forward-looking statements, whether as a result of circumstances or events occurring after the date hereof, new information or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210921005189/en/

CONTACT: Alexa Huerta

Investor Relations

Phone 214 937 3190

alexahuerta@orthofix.com Denise Landry

Media relations

Phone 214 937 2529

deniselandry@orthofix.com

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY SURGERY MEDICAL DEVICES HEALTH PHYSICAL THERAPY

SOURCE: Orthofix Medical Inc.

Copyright Business Wire 2021.

PUB: 09/21/2021 7:00 a.m. / DISC: 09/21/2021 7:02 a.m.

http://www.businesswire.com/news/home/20210921005189/en

Copyright Business Wire 2021.


Source link

]]>
https://imphos.org/orthofix-announces-full-market-launch-of-opus-mg-set-a-curable-magnesium-bone-filler-for-orthopedic-procedures-business/feed/ 0
Long-term investment will bring potential growth opportunities to key players – Bulk Solids Handling https://imphos.org/long-term-investment-will-bring-potential-growth-opportunities-to-key-players-bulk-solids-handling/ https://imphos.org/long-term-investment-will-bring-potential-growth-opportunities-to-key-players-bulk-solids-handling/#respond Mon, 20 Sep 2021 16:40:25 +0000 https://imphos.org/long-term-investment-will-bring-potential-growth-opportunities-to-key-players-bulk-solids-handling/ The research report “Triethyl phosphate market” provides an insightful database of who is already a big player in this industry or who is trying. Triethyl Phosphate Market Research provides market competition growth forecast, shared values, strategies, growth factors, market statistics, and strong industry analysis. The Triethyl Phosphate market report provides an assessment of factors driving […]]]>

The research report “Triethyl phosphate market” provides an insightful database of who is already a big player in this industry or who is trying. Triethyl Phosphate Market Research provides market competition growth forecast, shared values, strategies, growth factors, market statistics, and strong industry analysis. The Triethyl Phosphate market report provides an assessment of factors driving the market growth along with emerging economic trends in the market. This report provides consolidated and updated information relevant to the industry.

For more information and a full list of key players, get our free sample report: “Click here!” “

Lanxess, Eastman, Ningguo Long Day Chemical, Jilin Yonglin, Hongzheng Chemical, Donghu Chemical is the main organization that dominates the world market.
(* Note: other players can be added on request)

Triethyl Phosphate Market Segmentation By Type:

Industrial quality, superior quality

Triethyl Phosphate Market Segmentation Based On Applications:

Chemical catalyst, flame retardant, organic solvent, pesticide intermediates, others

Research methodology

Worldwide Market Reports uses a comprehensive and iterative research methodology focused on variance minimization to provide the most accurate estimates and forecasts possible. The company uses a combination of bottom-up and top-down approaches to segment and estimate quantitative aspects of the market. Additionally, a recurring theme in all research reports is data triangulation, which examines the market from three different perspectives.

Preliminary data mining

Raw market data is gathered and collated from a wide range of fronts. Data is continuously filtered to ensure that only verified and certified sources are considered. The data is also pulled from several reports in our repository and several reputable paid databases. Understanding and facilitating the entire value chain is essential for a comprehensive understanding of the market. We collect data from raw material suppliers, distributors and buyers.

statistical model

Our market estimates and forecasts are derived from simulation models. A unique model is created for each study. Information gathered on market dynamics, technology landscape, application development and price trends are fed into the model and analyzed simultaneously. These factors are studied on a comparative basis and their impact on the forecast period is quantified using correlation, regression and time series analyzes. Market forecasts are made through a combination of economic tools, technical analysis, industry experience and domain expertise.

COVID-19 impact assessment: The full version of the report includes the projected changes in the impact of COVID-19 and the future outlook for the industry, taking into account political, economic, social and technological parameters.

Get specific research based on COVID 19 analysis: https://www.worldwidemarketreports.com/covidimpact/720622

Some parameters taken into account for the prediction are:

  • Market drivers and constraints, as well as current and expected impacts
  • Product scenarios and supply trends versus prices
  • Regulatory scenarios and expected developments
  • Add current and projected capacity by 2027

We assign weights to these parameters and quantify the impact on the market using weighted average analysis to derive projected market growth rates.

Primary verification

This is the last step in forecasting and forecasting the report. An in-depth primary interview is conducted face to face and by telephone to validate the results and the assumptions used to obtain them. Interviewees are approached by leading companies across the value chain, including vendors, technology providers, subject matter experts and buyers, to ensure a holistic and unbiased picture of the market. These interviews are conducted around the world, where language barriers have been overcome with the help of local staff and interpreters. The main interview not only helps in data validation but also provides important market insights, current business scenarios and future expectations, and improves the quality of the report. All our estimates and projections are validated by exhaustive primary research with Key Industry Participants (KIPs), which typically include:

Leading company on the market
raw material supplier
product distributor
Buyer

Looking to buy? Get a discount on this research report: https://www.worldwidemarketreports.com/discount/720622

Customization of the report: Please let us know if you have any special requirements. We will provide the report as you want.


Source link

]]>
https://imphos.org/long-term-investment-will-bring-potential-growth-opportunities-to-key-players-bulk-solids-handling/feed/ 0
Global Biofertilizer Market Outlook, Latest Trends and Forecast to 2030 | Key players – Sigma AgriScience, LLC., Bio Power Lanka, Rizobacter Argentina SA (Rizobacter), Novozymes A / S https://imphos.org/global-biofertilizer-market-outlook-latest-trends-and-forecast-to-2030-key-players-sigma-agriscience-llc-bio-power-lanka-rizobacter-argentina-sa-rizobacter-novozymes-a-s/ https://imphos.org/global-biofertilizer-market-outlook-latest-trends-and-forecast-to-2030-key-players-sigma-agriscience-llc-bio-power-lanka-rizobacter-argentina-sa-rizobacter-novozymes-a-s/#respond Mon, 20 Sep 2021 12:30:19 +0000 https://imphos.org/global-biofertilizer-market-outlook-latest-trends-and-forecast-to-2030-key-players-sigma-agriscience-llc-bio-power-lanka-rizobacter-argentina-sa-rizobacter-novozymes-a-s/ Global Biofertilizer Market The Absolute Markets Insights report is a well-thought-out compilation of detailed market development and growth factors optimizing the path for continued growth in terms of accurate product data, strategies and market share of leading companies on this particular market. We follow an iterative model of research methodology to formulate the report which […]]]>

Global Biofertilizer Market The Absolute Markets Insights report is a well-thought-out compilation of detailed market development and growth factors optimizing the path for continued growth in terms of accurate product data, strategies and market share of leading companies on this particular market. We follow an iterative model of research methodology to formulate the report which helps decision makers make an informed investment assessment. Literature research is conducted using internal and external sources to obtain qualitative and quantitative market information supported by primary research.

Leading market players presented in the Biofertilizers Market report include: Sigma AgriScience, LLC., Bio Power Lanka, Rizobacter Argentina SA (Rizobacter), Novozymes A / S (Novozymes), Lallemand Inc. (LALLEMAND Inc.), Gujarat State Fertilizers and Chemicals Ltd. (GSFC), National Fertilizers Limited, Risehop, and AZOMURES (Azomure) among others.

Obtain an exclusive copy of this report at: https://www.absolutemarketsinsights.com/request_sample.php?id=155

Organic fertilizer is a substance made up of living microorganisms that help plants grow by increasing their nutrient supply. The increase in the use of organic fertilizers is expected to reduce the demand for chemical fertilizers and pesticides as they adversely affect the health of the soil. The aim of this report is to provide an overview of current and projected trends in the global Biofertilizers market and to conduct an in-depth analysis of the available market potentials. The report analyzes opportunities in developed and emerging economies so that companies can make strategic decisions and gain competitive advantage. There are some factors acting as the drivers of the biofertilizer market, such as increasing environmental awareness, improving soil fertility, and increasing demand for organic food. The factors that are holding back the growth of organic fertilizer market are lack of awareness and lower adoption rate by farmers. The unmet demand for fertilizers, the formulation of favorable government policies and countries with dominant agricultural economies would provide growth opportunities for this market.

The Biofertilizers Market report provides a complex overview of the industry including definitions and classifications. Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. The study gives a complex examination of its applications, including a detailed costing analysis of the products available in the global market with respect to the profit margins of the existing manufacturers. It helps to understand the major driving forces of the market in large end-use companies around the world. It is also a broad survey of market restraints, industry structure, and business model of the Biofertilizers market. Meetings and interviews with major market players have been used in order to present primary information regarding the market.

Inquiry Before Purchasing This Premium Report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=155

Confidence current state analysis tools such as Porter’s five forces analysis and SWOT analysis are used in the report to assess Biofertilizers market data to deploy comprehensive overview of the market. Moreover, this report gives a comprehensive examination of the scale and scope of the market globally. A detailed overview of the purchasing criteria and the difficulties encountered in the Biofertilizers business sector is also elaborated in this report.

Reasons to buy this report:

  • Our reports have been reviewed by professional industry experts, making them beneficial to the business to maximize their return on investment.
  • The analysis recognizes that sector actors and the main drivers of conflict and growth assess the impact of limitations as well as opportunities on the sector.
  • Data regarding the industry share by each item fragment, as well as their reasonable value, has been provided in the report.
  • We provide statistical insights, strategic and analytical tool results to provide sophisticated landscape and target key market players. This will help the business to increase its efficiency.
  • Our report helps readers to decipher current and future market restraints and optimal business strategies to enhance market development.

Some questions addressed in this report:

  • Which regions will continue to remain the most profitable regional markets for Biofertilizers market players?
  • What factors will induce a change in demand for Biofertilizers during the evaluation period?
  • What will be the impact of changing trends on the Biofertilizers market?
  • How can the market players seize the opportunities at hand in the Biofertilizers Market in the developed regions?
  • Which companies are dominating the Biofertilizers market?
  • What are the winning strategies of the Biofertilizers market players to gain momentum in this landscape?

Customization request: https://www.absolutemarketsinsights.com/request_for_customization.php?id=155

Global segmentation of the Biofertilizers market:

By product type:

  • Nitrogen fixation
  • Phosphate-Solubilizer
  • Potash-Mobilization
  • Others (Zinc, Boron or Sulfur-Solubilizer)

By microorganisms:

  • Azospirilla
  • Cyanobacteria
  • Phosphate solubilizing bacteria
  • Azolla
  • Aulosira
  • Rhizobium
  • Azotobacter
  • Other

By culture:

  • Cereals and cereals
  • Legumes and oilseeds
  • Fruits and vegetables
  • Fiber crops
  • Others (plantation crops, forage crops)

By application:

  • Seed treatment
  • Soil treatment
  • Root dip

By form:

  • Pure and mixed liquid fermentations
  • Powder
  • Dispersible granulate
  • Lozenge

By region:

  • North America [U.S., Canada, Mexico]
  • Europe [Germany, UK, France, Italy, Rest of Europe]
  • Asia Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
  • South America [Brazil, Argentina, Rest of Latin America]
  • Middle East and Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

Thank you for reading the entire article. If you want to know more about the Biofertilizers market, looking for customization, contact us. To achieve full keyword reach in the market, or to learn more about opportunities, contact our research analyst. Our team is available 24/7 to assist and support our clients with reliable research.

For more information, click on: https://www.absolutemarketsinsights.com/reports/Biofertilizers-market-2018-2026-155

Contact us:

Company: Absolute Markets Insights

Email ID: sales@absolutemarketsinsights.com

Phone: + 91-740-024-2424

Contact Name: Shreyas Tanna

The working laboratory,

Model colony, Shivajinagar, Pune, MH, 411016

Website: https://www.absolutemarketsinsights.com


Source link

]]>
https://imphos.org/global-biofertilizer-market-outlook-latest-trends-and-forecast-to-2030-key-players-sigma-agriscience-llc-bio-power-lanka-rizobacter-argentina-sa-rizobacter-novozymes-a-s/feed/ 0
Global Consumer Electronics Lithium Ion Battery Market Share, Size, Global Development, Growth Status, Revenue, Emerging Technologies, Key Player Analysis, Assessment of Opportunities, and Industry Expansion Strategies 2027 https://imphos.org/global-consumer-electronics-lithium-ion-battery-market-share-size-global-development-growth-status-revenue-emerging-technologies-key-player-analysis-assessment-of-opportunities-and-industry-ex/ https://imphos.org/global-consumer-electronics-lithium-ion-battery-market-share-size-global-development-growth-status-revenue-emerging-technologies-key-player-analysis-assessment-of-opportunities-and-industry-ex/#respond Sun, 19 Sep 2021 13:17:31 +0000 https://imphos.org/global-consumer-electronics-lithium-ion-battery-market-share-size-global-development-growth-status-revenue-emerging-technologies-key-player-analysis-assessment-of-opportunities-and-industry-ex/ “A SWOT analysis of Lithium-ion batteries for consumer electronics, Professional investigation report including analysis of major global players with CAGR and stock market rising and falling. “ The report on the “Lithium-ion batteries for the consumer electronics market”Studies existing and future visions of the global lithium-ion battery market for consumer electronics. It includes a detailed […]]]>

“A SWOT analysis of Lithium-ion batteries for consumer electronics, Professional investigation report including analysis of major global players with CAGR and stock market rising and falling. “

The report on the “Lithium-ion batteries for the consumer electronics market”Studies existing and future visions of the global lithium-ion battery market for consumer electronics. It includes a detailed overview of the global lithium-ion batteries for consumer electronics market along with market images. Further, it offers comprehensive data on the various segments of the global Lithium-Ion Batteries for Consumer Electronics market research. The report analyzes each segment of the global lithium-ion batteries for consumer electronics market on the basis of application, end-user, and region. Besides, it also highlights the dominant players in the market along with their market share. Well-established players in the market are GS Yuasa, BYD, LG Chem, Samsung, Toshiba, Johnson Controls, Hitachi, Panasonic, BAK.

The Global Consumer Electronics Lithium-Ion Batteries Market report is assessed on the basis of the revenue (USD Million) and size (k.MT) of the Global Consumer Electronics Lithium-Ion Batteries Market consumer electronics. It analyzes various market dynamics such as drivers, limitations, and opportunities impacting the Lithium-Ion Batteries for Consumer Electronics market. It also predicts the influence of these key elements on the growth of the Lithium Ion Batteries for Consumer Electronics market over the coming period. Through the study of market shares, the competitive scenario of the dominant market players is assessed.

The report demonstrates the current trends and strategies adopted by the major market players. This analysis helps the major and new market players to strengthen their positions and increase their share in the global lithium-ion batteries for consumer electronics market. The data presented in the Global Consumer Electronics Lithium-Ion Batteries Market research report helps market players to position themselves firmly in the global Consumer Electronics Lithium-Ion Batteries Market.

Additional geographic segments are also mentioned in the empirical report.

North America: United States, Canada, rest of North America
Europe: United Kingdom, Germany, France, Italy, Spain, Rest of Europe
Asia Pacific: China, Japan, India, Southeast Asia, North Korea, South Korea, Rest of Asia-Pacific
Latin America: Brazil, Argentina, Rest of Latin America
Middle East and Africa: GCC countries, South Africa, Rest of Middle East and Africa

Read the detailed index of the full research study at: https://www.marketresearchstore.com/market-insights/lithium-ion-batteries-for-consumer-electronics-market-818983

The research report includes features that are contributing to and influencing the expansion of the global Consumer Electronics Lithium-Ion Batteries market. It projects the market valuation for the expected time. The report further indicates recent market trends and key perspectives contributing to the growth of the lithium-ion batteries for consumer electronics market in the future. In addition, the main product types and segments Lithium Nickel Manganese Cobalt (LI-NMC), Lithium Iron Phosphate (LFP), Lithium Cobalt Oxide (LCO), Lithium Titanate Oxide (LTO), Lithium Manganese Oxide (LMO), Lithium Nickel Cobalt Aluminum Oxide (NCA) as well as Laptops, Tablets, DVD Players, Portable CD Players, Digital Cameras, Smartphones, Camcorders, Wearable Devices sub-segments of the global market are covered in the report.

On a regional basis, the market is categorized into five regions such as North America, Latin America, Middle East Africa, Asia-Pacific, and Europe. The report also demonstrates the impact of Porter’s five forces in the global consumer electronics lithium-ion battery market. The report covers the important data of the Lithium Ion Batteries for Consumer Electronics market in the form of tables, charts and images.

Impact of COVID-19

The most recent report includes extensive coverage of the significant impact of the COVID-19 pandemic on the Heated Vests division. The coronavirus epidemic has a huge impact on the global economic landscape and therefore on this particular industry. Therefore, the report offers the reader a clear concept of the current scenario of this industry and estimates the consequences of COVID-19.

There are 15 Chapters to display the global Consumer Electronics Lithium Ion Battery market

Chapter 1, definition, specification and classification of lithium-ion batteries for consumer electronics, applications of lithium-ion batteries for consumer electronics, market segment by regions;
Chapter 2, Structure of manufacturing costs, raw materials and suppliers, manufacturing process, industrial chain structure;
Chapter 3, Analysis of technical data and manufacturing plants of lithium-ion batteries for consumer electronics, capacity and commercial production date, distribution of manufacturing plants, state of R&D and source of technology, analysis of raw material sources;
Chapter 4, Global Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sale Price Analysis (Company Segment);
Chapter 5 and 6, Regional market analysis which includes United States, China, Europe, Japan, Korea and Taiwan, Consumer electronics lithium-ion battery segment market analysis (by type);
Chapter 7 and 8, Consumer Electronics Lithium-Ion Battery Segment Market Analysis (By Application) Major Manufacturers Analysis of Consumer Electronics Lithium-Ion Batteries;
Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Lithium Nickel Manganese Cobalt (LI-NMC), Lithium Iron Phosphate (LFP), Lithium Cobalt Oxide (LCO), Lithium Titanate Oxide (LTO), Lithium Manganese Oxide (LMO)), Lithium Nickel Cobalt Aluminum Oxide (NCA), Market Trend by Application Laptops, tablets, DVD players, portable CD players, digital cameras, smartphones, camcorders, portable devices;
Chapter 10, Analysis of the type of regional marketing, Analysis of the type of international trade, Analysis of the supply chain;
Chapter 11, Consumer analysis of global lithium-ion batteries for consumer electronics;
Chapter 12, Lithium-Ion Batteries for Consumer Electronics Research Findings and Conclusion, Appendix, methodology and data source;
Chapter 13, 14 and 15, Lithium Ion Batteries Sales Channel for Consumer Electronics, Distributors, Traders, Resellers, Research Findings and Conclusion, Appendix and Data Source.

Inquire Here Get Personalization and Check Discount for Report @: https://www.marketresearchstore.com/inquiry/lithium-ion-batteries-for-consumer-electronics-market-818983

Reasons to buy lithium-ion batteries for the consumer electronics market

  • This report provides an accurate analysis of changing competitive dynamics
  • It provides a forward-looking perspective on the various factors driving or restraining the growth of the market
  • It provides a six-year forecast evaluated on the basis of how the market is predicted to grow.
  • It helps to understand key product segments and their future
  • It provides accurate analysis of changing competitive dynamics and keeps you one step ahead of your competition
  • It helps to make informed business decisions by having a comprehensive view of the market and performing in-depth analysis of market segments

Thank you for reading this article; you can also get a section by chapter or a report version by region, such as North America, Europe or Asia.

About the Market Research Store

At Market Research Store, we provide reports on a range of industries such as Healthcare & Pharmaceuticals, Automotive, IT, Insurance, Safety, Packaging, Electronics & Semiconductors, medical devices, food and beverage, software and services, manufacturing and construction, defense and aerospace, agriculture, consumer goods and retail, etc. Every aspect of the market is covered in the report with its regional data. Market Research Store is committed to meeting the demands of our customers, offering tailor-made solutions best suited to strategy development and execution to achieve substantial results. Beyond that, we will be available to our customers 24/7.

Ask questions / Buy a report directly by contacting us @ sales@marketresearchstore.com

Contact us:

Market research store
3422 SW 15 Street, Costume # 8138,
Deerfield Beach, Florida 33442, USA
Phone. : + 1-386-310-3803GMT
Phone. : + 49-322 210 92714
Website: https://www.marketresearchstore.com


Source link

]]>
https://imphos.org/global-consumer-electronics-lithium-ion-battery-market-share-size-global-development-growth-status-revenue-emerging-technologies-key-player-analysis-assessment-of-opportunities-and-industry-ex/feed/ 0
Harnessing the fashion rush to exploitation https://imphos.org/harnessing-the-fashion-rush-to-exploitation/ https://imphos.org/harnessing-the-fashion-rush-to-exploitation/#respond Sun, 19 Sep 2021 10:55:44 +0000 https://imphos.org/harnessing-the-fashion-rush-to-exploitation/ The fashion industry currently holds many jobs. It is meeting a basic need, serving a purpose of expression, preserving crops, producing a brilliant amount of carbon emissions and filling all possible rivers with toxic scum. An industry-encompassed subculture called Fast Fashion is the most worked segment of them all. By keeping activists on their toes, […]]]>

The fashion industry currently holds many jobs. It is meeting a basic need, serving a purpose of expression, preserving crops, producing a brilliant amount of carbon emissions and filling all possible rivers with toxic scum. An industry-encompassed subculture called Fast Fashion is the most worked segment of them all. By keeping activists on their toes, companies that promote this culture ensure that in addition to sufficient ecological damage, an unhealthy environment for workers is also created.

Fast fashion refers to the rapid production of inexpensive clothing in line with the demands of high-end fashion. Over the past two decades, this business model has grown tremendously. Clothing manufacturing doubled between 2000 and 2014 and clothing purchased per capita increased by 60 percent. This trend has not gone unnoticed. The quick fashion review is a conversation that has been around for years now.

An average consumer throws 60 percent of their clothes the first year itself. The predominant perspective of consumers to constantly buy clothes to keep up with trends has kept the situation from improving. With this in mind, companies prefer to invest in styles and designs rather than raw materials. Retailers like Zara and H&M have claimed that around 40 to 53% of their products in stock are less than 3 months old. Fast-fashion giant Shein, the world’s largest online-only retailer, launches around 700-1,000 new items every day, as its CEO said. Molly miao. This approach of quantity over quality gave way to two major issues, one being ecological damage and the other being the exploitation of labor.

The the fashion industry is responsible for more than 10 percent of carbon emissions and consumes around 100 million tonnes of oil each year. Virgin polyester is a key part of these numbers. The one-year manufacturing process of virgin polyester produces the same amount of CO2 than 180 coal-fired power plants, which represents around 700 million tonnes of CO2 per year. Reports estimate that this could double again by 2030. The fThe auto industry emits as many greenhouse gas emissions each year as the economies of France, Germany and the UK combined, according to McKinsey researchers. The recent report by The United Nations Intergovernmental Panel on Climate Change (IPCC) made the discussion even more imperative, as it called climate change a “code red for humanity”.

In addition to greenhouse gas emissions, manufacturing units discharge toxic wastewater with a high phosphate content into rivers. In Delhi, for more than 33 days in 2020, the ammonia level in the water has remained above treatable levels, directly impacting over a third of Delhi’s water supply. Rural India plays a major manufacturing and dyeing role for many clothing companies. These effluents pollute the drinking water of the villagers and make cultivation difficult. The water crisis in Punjab with the depletion of groundwater levels is a recent problem, something the Punjab is still going through, and these industries are only making matters worse.

Not just the production, the disposal of these clothes is also a mess. According to a Ellen Macarthur Foundation report, if things continue as they are, more than

150 million tonnes of clothes will end up in landfills or be incinerated in 2050. Each second, a garbage truck clothing value is thrown away or burned.

This stifling climate system, to add to the misery, is built on the backbone of workers working long hours and meager wages. The need to be competitive in the market motivates most companies to cut all costs possible, with labor wages being an easy target. Companies make sure to choose locations with cheap labor costs and limited worker rights. Countries like China, India and Bangladesh offer great options as a massive population paves the way for extremely low wages for many hours of work. Unemployment being a major problem, it is a well-known situation in India. The workers are all employed days a week and often refused overtime payment. The pandemic has only worsened the situation and without government intervention the future is bleak.

The working conditions are another appalling sight. Lack of ventilation, inhalation of fiber dust and other toxic substances are a daily routine. Forced labor and child labor would be a whole different article.

The voices around Fast Fashion’s operating economy, right now, are louder than ever. People’s concern grew around the work lines of fashion companies, forcing many large companies to speak out. Companies like Levi’s, Wrangler, H&M, among others, have started to make small efforts towards sustainability, piloting products with a increased amount of hemp cotton, detachable accessories and reduced water consumption being some of them. Zara also claimed to use 100% sustainable fabrics by 2025. Although this should only be the beginning, the end goal being to fully embrace the concept of circularity; a system where we no longer extract new materials from the earth.

Looking at the bright side, a lot of new companies with better alternatives are emerging in the textile space. A Delhi-based textile start-up ‘Aslee‘uses materials like nettle, hemp, and bamboo to bring about change. Other sustainable brands worth mentioning are ‘Harago’, ‘Amesh’ and ‘Petit Pli’.

When it comes to working conditions, the Make in India initiative has given Indian workers more space and rights in this ruthless industry. But with the pandemic enveloping the entire world, the situation has stumbled on a steep slope. Conditions are improving now, with an increase in vaccinations most likely, but we still have a long way to go.

Returning to pre-Covid conditions is not the goal, the bar is much higher. Workers’ rights, as mentioned above, are in urgent need of attention and improvement. In addition, the fashion industry is still not regulated in terms of environmental impact, which needs to be looked at. Society cannot wait for the dawn of realization to fall on capitalism, regulation is the only way, at least as far as the ecosystem is concerned.


Source link

]]>
https://imphos.org/harnessing-the-fashion-rush-to-exploitation/feed/ 0
Following a new report bolstering production and supplier details, Apple Car is on the rise again. https://imphos.org/following-a-new-report-bolstering-production-and-supplier-details-apple-car-is-on-the-rise-again/ https://imphos.org/following-a-new-report-bolstering-production-and-supplier-details-apple-car-is-on-the-rise-again/#respond Fri, 17 Sep 2021 19:49:44 +0000 https://imphos.org/following-a-new-report-bolstering-production-and-supplier-details-apple-car-is-on-the-rise-again/ Rumors that Cupertino tech giant Apple Inc is considering making a hypothetical electric vehicle continue to linger in the market. According to a report by Taiwanese media DigiTimes, Apple, which is currently working on a vehicle dubbed “Apple Car”, will enter mass production of the vehicle in a few years. This is the second time […]]]>

Rumors that Cupertino tech giant Apple Inc is considering making a hypothetical electric vehicle continue to linger in the market. According to a report by Taiwanese media DigiTimes, Apple, which is currently working on a vehicle dubbed “Apple Car”, will enter mass production of the vehicle in a few years. This is the second time that rumors of the vehicle’s entry into production have surfaced. Today’s report matches its timeline with a Reuters precedent that surfaced in December of last year.

Additionally, today’s report also reiterates an assumed mass production schedule for the vehicle. DigiTimes believe the Apple Car could go into mass production in 2024, which was mentioned in a previous Reuters report. This report, which surfaced in December last year, pointed out that Apple was comfortable enough with its designs for a 2024 mass production schedule, but warned that the chain delays supply, especially those resulting from the ongoing pandemic, could postpone it until 2025.

Apple reportedly considering partnerships with Korean battery and powertrain for so-called Apple car
The DigiTimes report, hidden behind a paywall, says Apple is in talks with automakers and Apple Car suppliers. The few details available suggest the company is in talks with South Korean manufacturers of batteries and memory for the vehicle. Specifically, DigiTimes reports that Apple representatives visited LG Electronics and SK Group. The former’s chemical division, LG Chem, makes batteries for Palo Alto, Calif., Electric vehicle maker Tesla Inc. The latter is known for its memory modules and has other divisions as well. Previous reports have also mentioned Korean companies, suggesting that the battery manufacturing arm of SK Hynix SK Innovation and LG Magna e-Powertrain, a Canadian joint venture, were involved.

He also revealed that Apple was interested in light sensing and telemetry (LiDar) sensors for the vehicle and that a unique ‘single-cell’ battery design would increase the vehicle’s range compared to its potential competitors because it would allow Apple to integrate more energy components inside the battery. pack. Apple was also reportedly interested in lithium phosphate (LP) for battery materials because of its safety.

My favorite story about the Apple Car Project – before the reset heralded by the return of Doug Field – is that they actually had a concept for an Apple designed and branded car. And they added it all up and it turned out so expensive that they had to seriously hit the reset button. This is how it goes, no shame in it.

A concept rendered from the rumored Apple Car by CarWow.
Commenting on the rumors, Tesla chief Mr. Elon Musk, whose company remains the only US manufacturer to have successfully mass produced electric vehicles, said the report was “strange.”

I’m pretty sure Apple has a very talented team, even a division, working hard on this, and may well come up with the iPhone in cars. But I’ll take all the news related to Project Titan with a grain of salt until we see something real.

Apple car
Rumors have suggested that current Apple chief Mr. Tim Cook is unlikely to announce the Apple car during his remaining tenure.
Today’s report also follows an analyst note from Morgan Stanley, with analysts at the bank stressing that Apple needs to properly design the car before proceeding with its integration into its service ecosystem.

Analyst Katy Huberty, in a note courtesy of fellow senior Apple reporter Phillip Elmer-Dewitt, said: Right. Well first let me reiterate something because I get this question often. Does Apple Really Want To Build A Car? Why don’t they just focus on software and services? Apple succeeds when they are vertically integrated. They want to participate in the design, in how software communicates with hardware, what the right components and technologies are to use. And so, well, yeah, any great tech, the most important value is in terms of profit in dollars but also in terms of alpha generated by investors and in terms of software and services of course. But Apple will focus just as much on the other elements – build, design, what that vehicle looks like, how the components and the software work together – as it will on services.

So I want to reiterate this because it comes up so often. And finally – and they proved it with the phone just recently – that services in total account for over 20% of Apple’s revenue. Yet the iPhone is half the business. Thus, they cannot be successful in services until they succeed in selling the device on which this new type of computer and service is based. So I wouldn’t put the cart before the horse. Yes, there will be an important element around the services that will become available in an automobile once the driver’s focus and attention is released, but they must first master the car. You and I have already discussed this. I wouldn’t be surprised if Apple hits the market with an EV, right? A car that resembles the automobiles currently on the market with a steering wheel. They did it with the iPhone where in the first iPhone there was no app store. The first step was to get the right material. How do you differentiate yourself on the material? It was a bigger screen that ultimately paved the way for Netflix and playing video games and what you have on this device. I think the focus right now, I’m sure, is on the design and the vehicle itself, but with some thoughtful plans around what services might emerge in the longer term.

Elmer commented that the “cart” is the software and services in this scenario, while the “horse” is the actual hardware. Apple’s main manufacturing partner, Taiwan-based Hon Hai Precision Industry Co. Ltd., is also expanding its electric vehicle segment. Still, given the current lack of details for the Apple Car, it’s unclear how Apple will proceed towards mass production, which is one of the more difficult aspects of a vehicle. The author has no position in any of the actions mentioned. WCCF TECH INC has a disclosure and ethics policy.
SHARE THE TWEET

Summary of the news:

  • Following a new report bolstering production and supplier details, Apple Car is on the rise again.
  • Check out all the news and articles about the latest security updates.

Disclaimer: If you need to update / change this article, please visit our help center.


For the latest updates Follow us on googIe New


Source link

]]>
https://imphos.org/following-a-new-report-bolstering-production-and-supplier-details-apple-car-is-on-the-rise-again/feed/ 0
Comprehensive Hyperphosphatemia Drugs Market Report 2021 | Size, Growth, Demand, Opportunities and Forecast to 2027 https://imphos.org/comprehensive-hyperphosphatemia-drugs-market-report-2021-size-growth-demand-opportunities-and-forecast-to-2027/ https://imphos.org/comprehensive-hyperphosphatemia-drugs-market-report-2021-size-growth-demand-opportunities-and-forecast-to-2027/#respond Fri, 17 Sep 2021 14:11:34 +0000 https://imphos.org/comprehensive-hyperphosphatemia-drugs-market-report-2021-size-growth-demand-opportunities-and-forecast-to-2027/ Hyperphosphatemia is a condition in which the level of phosphate in the blood is increased. This condition can be caused by the displacement of phosphate from the intracellular space to the extracellular space, excessive supply of phosphate, and decreased excretion of phosphate. High levels of phosphate in the blood can be avoided through dietary restrictions […]]]>

Hyperphosphatemia is a condition in which the level of phosphate in the blood is increased. This condition can be caused by the displacement of phosphate from the intracellular space to the extracellular space, excessive supply of phosphate, and decreased excretion of phosphate. High levels of phosphate in the blood can be avoided through dietary restrictions and the use of phosphate binders.

Hyperphosphatemia Drugs Market research is an intelligence report with meticulous efforts undertaken to study accurate and valuable information. The data that has been examined is done taking into account both the best existing players and the future competitors. The report assesses and ranks the vendors in the Hyperphosphatemia Drugs market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for business). ‘money, ease of use, product features and customer support) that helps businesses make better decisions and understand the competitive landscape.

Global Hyperphosphatemia Drugs Market Size Expected to Register Significant CAGR of + 15% by 2027

Get a sample copy of this report with the latest industry trends and COVID-19 impact @: https://www.a2zmarketresearch.com/sample?reportId=283734

Some of the best companies influencing this market include: OPKO Health, Inc., Baxter International Inc., Natco, Torii Pharmaceutical, Bayer, Novartis, Keryx Biopharmaceuticals, Mylan, Kyowa Hakko Kirin, Fresenius Medical Care, Shire, Kissei Pharmaceutical, Chugai Pharmaceutical, Sanofi, Japan Tobacco, Vifor Pharma, Amgen

The business strategies of major Hyperphosphatemia Drugs players and new industries of the entering market are studied in detail. A well explained SWOT analysis, revenue share and contact details are shared in this report analysis. It also provides information on the market in terms of development and its capabilities. Various factors are responsible for the growth trajectory of the market, which are discussed at length in the report. Additionally, the report lists restraints that pose threat to the global Hyperphosphatemia Drugs market.

Global Hyperphosphatemia Drugs Market Research Report Offers:

  • Identification and analysis of the micro and macro factors that have and will affect the growth of the market.
  • A comprehensive listing of major market players operating in the global Hyperphosphatemia Drugs Market.
  • Analysis of different market segments such as type, size, applications and end users.
  • Market definition of the Global Hyperphosphatemia Drugs Market along with the analysis of different influencing factors such as drivers, restraints, and opportunities.
  • In-depth research on the competitive landscape of global hyperphosphatemia drugs
  • It offers a descriptive analysis of the supply-demand chaining in the global Hyperphosphatemia Drugs market.
  • Statistical analysis of some significant economic facts
  • Figures, tables, graphs, images to clearly describe the market.

Get up to 30% off the first purchase of this report @: https://www.a2zmarketresearch.com/discount?reportId=283734

The cost analysis of the global Hyperphosphatemia Drugs market has been done considering the expenditure for manufacturing, the cost of labor and raw materials, along with their market concentration rate, their suppliers and price trends. It also assesses the bargaining power of suppliers and buyers, the threat of new entrants and substitutes, and the degree of competition prevailing in the market. The influence of the latest government directives is also analyzed in detail in the report. It studies the trajectory of the Hyperphosphatemia Drugs market between forecast periods.

Global Segmentation of Hyperphosphatemia Drugs Market:

Market segmentation by type:

  • mainly divided into: _x000D_
  • Aluminum phosphate binder
  • Calcium phosphate binder
  • Phosphate binder without aluminum and calcium
  • Magnesium phosphate binder
  • Iron phosphate binder

Market segmentation by application:

Regions Covered By The Global Hyperphosphatemia Drugs Market 2020 Report:
The Middle East and Africa (GCC countries and Egypt)
North America (United States, Mexico and Canada)
South America (Brazil etc …)
Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Table of Contents (TOC)

Global Hyperphosphatemia Drugs Market Report 2020 – Growth, Trend and Forecast Till 2026

Chapter 1 Hyperphosphatemia Drugs Market Overview

Chapter 2 Global Economic Impact on Hyperphosphatemia Drugs Industry

Chapter 3 Global Hyperphosphatemia Drugs Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region (2014-2020)

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions (2014-2020)

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Analysis of Manufacturing Costs

Chapter 9 Industry Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors / Traders

Chapter 11 Analysis of Market Effect Factors

Chapter 12 Global Hyperphosphatemia Drugs Market Forecast (2020-2026)

Chapter 13 Appendix

Buy an exclusive report @: https://www.a2zmarketresearch.com/buy?reportId=283734

If you have any special requirements, please let us know and we will offer you the report you want.

About A2Z Market Research:

A2Z Market Research Library provides market research syndication reports from around the world. Buy-to-buy syndication Market research will help you find the most relevant business intelligence.

Our research analyst provides business information and market research reports for large and small businesses.

The company helps its clients to develop trade policies and grow in this market sector. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, catering, media, etc., but also your company data, country profiles, trends, news. and analysis on the sector that interests you.

Contact us:

Roger smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147


Source link

]]>
https://imphos.org/comprehensive-hyperphosphatemia-drugs-market-report-2021-size-growth-demand-opportunities-and-forecast-to-2027/feed/ 0